Adamis Pharmaceuticals Corp (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged for appraisal the company’s resubmitted New Drug Application (NDA) for ZIMHI™. FDA finishes filing appraisal and governs NDA adequately ample for fundamental appraisal Adamis has received FDA communication involving the company’s NDA, affirming […]